...
首页> 外文期刊>Korean journal of radiology : >Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism
【24h】

Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism

机译:微波消融对原发性甲状旁腺功能亢进的安全性和疗效的临床研究

获取原文
           

摘要

OBJECTIVE:To evaluate the safety, feasibility, and efficacy of microwave ablation (MWA) for the treatment of primary hyperparathyroidism (PHPT).MATERIALS AND METHODS:This study enrolled 67 PHPT patients (22 men, 45 women; mean age, 56.0 ± 16.3 years; range, 18-83 years) from January 2015 to December 2018. The laboratory data, including the serum intact parathyroid hormone (iPTH), calcium, phosphorus, and alkaline phosphatase (ALP) levels, were evaluated before MWA and again 2 hours, 1 day, 7 days, 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months after.RESULTS:Complete ablation was achieved with all 72 hyperplastic parathyroid glands found on the 67 patients enrolled, 64 of whom were treated in one session and 3 were treated over two sessions. The technical success rate was 100%. The median follow-up time was 13.6 months (range, 10.0-31.1 months). The clinical success rate was 89.4%. The volume reduction rate was 79.4% at 6 months. Compared to pre-MWA, the serum iPTH, calcium, phosphorus, and ALP levels had significantly improved 6 months post-MWA (iPTH, 157.3 pg/mL vs. 39.2 pg/mL; calcium, 2.75 ± 0.25 mmol/L vs. 2.34 ± 0.15 mmol/L; phosphorus, 0.86 ± 0.20 mmol/L vs. 1.12 ± 0.22 mmol/L; ALP, 79 U/L vs. 54 U/L, respectively; all, p 0.01). Hoarseness was a major complication in 4 patients (6.0%), but it improved spontaneously within 2-3 months.CONCLUSION:MWA is safe, feasible, and effective for the treatment of PHPT.Copyright ? 2020 The Korean Society of Radiology.
机译:目的:评价微波消融(MWA)治疗原发性甲状旁腺功能亢进(PHPT)的安全性,可行性和疗效。材料和方法:本研究招收了67例PHPT患者(22名男子,45名女性;平均年龄,56.0±16.3年从2015年1月到2018年12月的年度;范围,18-83岁。在MWA和再次2小时之前,评估实验室数据,包括血清完整甲状旁腺激素(IPTH),钙,磷和碱性磷酸酶(ALP)水平。 ,1天,7天,1个月,3个月,6个月,12个月,18个月和24个月后。结果:完全消融,所有72例过增殖的甲状旁腺,67名患者招生,其中64名在一个会议中治疗,3个会议接受了两次会议。技术成功率为100%。中位后续时间为13.6个月(范围,10.0-31.1个月)。临床成功率为89.4%。体积减少率在6个月内为79.4%。与MWA前,血清IPTH,钙,磷和ALP水平明显改善,6个月后6个月(IPTH,157.3 pg / ml与39.2 pg / ml;钙,2.75±0.25mmol / L与2.34 ±0.15mmol / L;磷,0.86±0.20mmol / L与1.12±0.22mmol / L; Alp,79 U / L与54 U / L分别;全部,P <0.01)。嘶哑是4名患者(6.0%)的主要并发症,但它在2-3个月内自发改善。结论:MWA是安全,可行的,治疗Phpt.copyright 2020韩国放射学会。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号